- Home
- EDIT
EDIT
Editas Medicine Inc.
as 07-26-2024 4:00pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 414.5M | IPO Year: | 2016 |
| Target Price: | $12.90 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.45 - $11.69 | Next Earning Date: | 08-05-2024 |
| Revenue: | $69,407,000 | Revenue Growth: | 204.54% |
| Revenue Growth (this year): | -58% | Revenue Growth (next year): | -27.08% |
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mei Baisong | EDIT | EVP, CHIEF MEDICAL OFFICER | Jul 19 '24 | Sell | $5.21 | 6,619 | $34,455.87 | 134,413 | SEC Form 4 |
| O'Neill Gilmore Neil | EDIT | CEO | Jun 4 '24 | Sell | $5.50 | 12,191 | $66,996.86 | 315,279 | SEC Form 4 |
| Mei Baisong | EDIT | EVP, CHIEF MEDICAL OFFICER | Jun 4 '24 | Sell | $5.50 | 511 | $2,808.25 | 141,032 | SEC Form 4 |
| Lucera Erick | EDIT | EVP, CHIEF FINANCIAL OFFICER | May 20 '24 | Sell | $5.61 | 22,337 | $125,404.39 | 116,829 | SEC Form 4 |
| Hopfield Jessica | EDIT | Director | May 13 '24 | Buy | $5.64 | 45,000 | $253,867.50 | 67,700 | SEC Form 4 |
| O'Neill Gilmore Neil | EDIT | CEO | Mar 2 '24 | Sell | $9.42 | 77,824 | $732,884.17 | 327,470 | SEC Form 4 |
| Mei Baisong | EDIT | SVP, CHIEF MEDICAL OFFICER | Mar 2 '24 | Sell | $9.42 | 20,327 | $191,425.46 | 141,543 | SEC Form 4 |
| Eaton Bruce | EDIT | EVP, CBO AND CTO | Dec 5 '23 | Sell | $10.90 | 103 | $1,122.41 | 74,791 | SEC Form 4 |
| Eaton Bruce | EDIT | EVP, CBO AND CTO | Nov 14 '23 | Sell | $8.21 | 695 | $5,705.67 | 74,894 | SEC Form 4 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
MT Newswires
18 days ago
RBC Cuts Price Target on Editas Medicine to $8 From $11, Keeps Sector Perform, Speculative Risk
Simply Wall St.
22 days ago
Editas Medicine (NASDAQ:EDIT) investors are sitting on a loss of 90% if they invested three years ago
Insider Monkey
a month ago
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
Insider Monkey
a month ago
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks with Highest Upside Potential?
Zacks
a month ago
Editas (EDIT) Reports Upbeat New Data From Reni-Cel Studies
MT Newswires
a month ago
Editas Medicine Says Its Gene Editing Potential Treatment for Sickle-Cell Disease Found Well-Tolerated in Phase 1/2 Trial
GlobeNewswire
a month ago
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
GlobeNewswire
a month ago
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
Compare EDIT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.